←
Edgewise Therapeutics692 posts
Edgewise Therapeutics avatar✓

Edgewise Therapeutics ✓

@EdgewiseTx

Biopharmaceutical company focused on therapeutics for cardiovascular diseases.

◷ Joined June 2021▧ 656 Photos and videos
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Nov 5

Today we announced a productive End-of-Phase 2 meeting with FDA for EDG-7500 in symptomatic hypertrophic cardiomyopathy (HCM). The Phase 3 protocol features tolerability-based dose escalation without safety echo monitoring. See the full press release here: investors.edgewisetx.com/new…

Post attachment
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Nov 2

At the @American_Heart’s Annual Scientific Sessions, we’ll present on EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction. Stop by booth #2812 to meet our team!

Post attachmentPost attachment
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Oct 9

We're excited to share the first data from our program in heart failure, EDG-15400, which we recently announced has now entered Phase 2. Find us at the Heart Failure Society of America’s 2026 Annual Scientific Meeting to discuss these findings.

Post attachmentPost attachment
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Oct 5

We’re attending Targeted Therapies and Emerging Options for Cardiomyopathies, a 3-day conference in Florence dedicated to cardiomyopathy care and research. Come visit our table to meet the team and learn about our ongoing work in cardiovascular disease.

Post attachment
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Jul 15

Hypertrophic cardiomyopathy (HCM) is a chronic heart disease characterized by thickening of the heart muscle. Edgewise is dedicated to improving the lives of people with serious cardiovascular diseases, including HCM. Visit edgewisetx.com/disease-areas….

0:51
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Jul 2

We're headed to the International Congress on Neuromuscular Diseases in Florence, Italy! Our team is looking forward to connecting with leaders in the neuromuscular space to advance the understanding, diagnosis, and care landscape.

Post attachment
Edgewise Therapeutics avatar
Edgewise Therapeutics@EdgewiseTx·Jun 24

Our team is looking forward to sharing the rationale, study design & baseline characteristics on our GRAND CANYON pivotal cohort (Poster A-26-20290) at the 12th Congress of the European Academy of Neurology (EAN)! Learn more: ean.org/congress2026

Post attachment